Imifoplatin is under clinical development by Promontory Therapeutics and currently in Phase II for Thymoma (Thymic Epithelial Tumor). According to GlobalData, Phase II drugs for Thymoma (Thymic Epithelial Tumor) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Imifoplatin LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Imifoplatin overview
PT-112 is under development for the treatment of advanced solid tumors including squamous or non-squamous non small cell lung cancer (NSCLC), basal cell carcinoma, pancreatic cancer, ovarian cancer, gallbladder cancer, gastric cancer, cholangiocarcinoma, colorectal cancer, thymoma, thymic carcinoma, neuroendocrine carcinoma, intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), metastatic hepatocellular carcinoma, urothelial carcinoma (UC), squamous cell carcinoma of the head and neck (SCCHN), castration-resistant prostate cancer (CRPC), breast cancer, liver cancer or hepatic metastasis and relapsed or refractory multiple myeloma. The drug candidate is administered intravenously. It is a phosphaplatin which is a combination of phosphate and platinum. It cats by targeting EIF2S1.
Promontory Therapeutics overview
Promontory Therapeutics is a clinical-stage pharmaceutical company developing phosphaplatins, a family of novel anti-cancer small molecule agents. Its lead product candidate PT-112, is a pyrophosphate-conjugated platinum therapeutic agent that combines apoptotic and immunogenic properties for preventing lung, breast cancer and hematological malignancies. Promontory Therapeutics works in collaboration with various contract research organizations, pharmaceutical companies and universities to study the mechanism of action of its lead drug candidate. It markets its products through its network of distributors across the US. Promontory Therapeutics is headquartered in New York City, New York, the US.
For a complete picture of Imifoplatin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
